SR
SRZNW
Surrozen, Inc./DE
$0.0170
0.00%
$197.4K
No data for this timeframe.
Vol
Market Cap$197.4K
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$19.00
Inst. Activity0 buys / 1 sells
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001824893·Prev Close $0.0170
Recent Activity
May 6, 2026
SEC
Surrozen reported Q1 2026 revenue of $5.0M, beating consensus estimate of $4.0M, driven by a $5M milestone payment from
8-K — Impact 4/10
Apr 1, 2026
SEC
This DEFA14A filing is a definitive proxy statement for Surrozen, Inc., filed by the registrant. It contains standard pr
DEFA14A — Impact 3/10
Mar 31, 2026
SEC
Surrozen, Inc.'s S-3 shelf registration has become effective, allowing the company to issue up to $200 million in securi
EFFECT — Impact 7/10
Inst.
UBS Group AG — TRIM
1,440 shares ($26.00)
Latest Reports
NEUTRAL
8-K
4/10
Surrozen reported Q1 2026 revenue of $5.0M, beating consensus estimate of $4.0M, driven by a $5M milestone payment from
May 6, 2026
NEUTRAL
DEFA14A
3/10
This DEFA14A filing is a definitive proxy statement for Surrozen, Inc., filed by the registrant. It contains standard pr
Apr 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $18.00 | TRIM |
| PRICE T ROWE ASSOCIATES | $1.00 | — |
2 institutional holders with $19.00 total value (43,055 shares) as of 2025-Q3. Top holders: UBS, PRICE.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 1,389 | $18.00 | 94.7% | TRIM -47.7% |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 41,666 | $1.00 | 5.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 2,754 | 1,440 | -47.7% | $26.00 | 2025-Q2 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
Surrozen reported Q1 2026 revenue of $5.0M, beating consensus estimate of $4.0M, driven by a $5M mil
May 6, 2026
NEUTRAL
DEFA14A
3/10
This DEFA14A filing is a definitive proxy statement for Surrozen, Inc., filed by the registrant. It
Apr 1, 2026
BEARISH
EFFECT
7/10
Surrozen, Inc.'s S-3 shelf registration has become effective, allowing the company to issue up to $2
Mar 31, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -11.6% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -11.6% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 68.8% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -40.8% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.